Compare Amgen, Inc. (AMGN) vs Valero Energy Corporation (VLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Valero Energy Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Valero Energy Corporation trades at $285.18 (market cap $83.35B). The key difference: Amgen, Inc. is far larger — about 2.4× Valero Energy Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | VLO | |
|---|---|---|
Market Cap | $196.12B | $83.35B |
Sector | Health | Energy |
52-Week High | $388.16 | $282.88 |
52-Week Low | $271.18 | $131.77 |
Enterprise Value | $241.41B | $89.10B |
Dividend Yield | 2.77% | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Valero Energy (VLO) trades at $280.69, down 0.2% on the day, with strong technical momentum as the stock approaches resistance near $285. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 expected at $10.03 EPS. Fundamentals show solid profitability with 17.72% ROE and improving cash flow projections for 2026. Recent news highlights strong refining margins and Gulf Coast operational advantages supporting the bullish outlook.
VLO presents a compelling investment case with strong earnings momentum and favorable industry dynamics, though investors face risks from energy market volatility and declining revenue trends. The stock trades above the consensus price target of $257.57, suggesting limited near-term upside despite 58% analyst buy ratings. The upcoming dividend payment of $1.20 provides additional shareholder return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
